Correction to: Efficacy and Safety of Supportive Care Biosimilars Among Cancer Patients: A Systematic Review and Meta‑Analysis

Size: px

Start display at page:

Download "Correction to: Efficacy and Safety of Supportive Care Biosimilars Among Cancer Patients: A Systematic Review and Meta‑Analysis"

厄岑
4 years ago
Views:

1 BioDrugs (2019) 33: CORRECTION Correction : Efficacy and Safety of Supportive Care Biosimilars Among Patients: A Systematic Review and Meta Analysis Jichun Yang 1 Shuqing Yu 1 Zhirong Yang 2 Yusong Yan 1 Yao Chen 1 Hongmei Zeng 3 Fei Ma 4 Yanxia Shi 5 Yehui Shi 6 Zilu Zhang 7 Feng Sun 1 Published online: 21 September 2019 Springer Nature Switzerland AG 2019 Correction : BioDrugs (2019) 33: https ://doi.org/ /s The authors unintentionally included in the meta-analysis both the initial abstract and the final paper of the by Puerlas et al. [45, 48]. In order remove this duplication, the following corrections are required. Page 373, abstract, results, line 1: The following sentence, which previously read: We identified 29 studies that compared of G-CSF or epoetin alfa: one RCT and five cohort studies (tal N = 2816) of epoetin alfa, and 13 RCTs and 10 cohort studies (tal N = 23,561) of G-CSF. should read: We identified 28 studies that compared of G-CSF or epoetin alfa: one RCT and five cohort studies (tal N = 2816) of epoetin alfa, and 13 RCTs and 9 cohort studies (tal N = 23,043) of G-CSF. The original article can be found online at https ://doi.org/ / s * Feng Sun sunfeng@bjmu.edu.cn Jichun Yang yangjichunya@163.com Shuqing Yu yushuqing@hsc.pku.edu.cn Zhirong Yang fsyz30147@163.com Yusong Yan yyan21@its.jnj.com Yao Chen @pku.edu.cn Hongmei Zeng hongmeizeng2011@163.com Fei Ma drmafei@126.com Yanxia Shi shiyx@sysucc.org.cn Yehui Shi shiyehui@tjmuch.com Zilu Zhang Zilu.zhang.us@gmail.com 1 Department of Epidemiology and Biostatistics, School of Public Health, Peking University, 38 Xueyuan Road, Haidian District, Beijing , China 2 Primary Care Unit, School of Clinical Medicine, University of Cambridge, Cambridgeshire CB1 8RN, UK 3 Department of Registry, National Center/National Clinical Research Center for / Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing , China 4 Department of Medical Oncology, National Center/National Clinical Research Center for / Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing , China 5 Department of Medical Oncology, Sun Yat-Sen University Center/State Key Laborary of Oncology in South China/Collaborative Innovation Center for Medicine, Guangzhou , China 6 7 Phase I Clinical Trial Department of Tianjin Medical University Institute and Hospital, Tianjin , China Harvard Medical School and Harvard Pilgrim Health Care Institute, Bosn, MA 02215, USA Vol.:( )

2 590 J. Yang et al. Page 377, fig. 1, the following text, which previously read: Box 8: Full-text excluded (n = 211) should read Fulltext excluded (n = 212) Duplicates: 91 should read Duplicates 92 Box 9: Full-text articles assessed for eligibility (n = 29) should read Full-text articles assessed for eligibility (n = 28) Box 10: Studies included in qualitative synthesis (n = 29) should read Studies included in qualitative synthesis (n = 28) Box 11: Studies included in quantitative synthesis (n = 29) should read Studies included in quantitative synthesis (n = 28) G-CSF :13 RCTs + 10 studies should read G-CSF :13 RCTs + 9 studies A corrected version of Fig. 1 is shown below: Page 379, Table 1, G-CSF vs. G-CSF section, Puerlas et al. (2016) [45] row: the entire row should be deleted. Page 379, Table 1, G-CSF vs. G-CSF section, Puerlas et al. (2018) [48] row: The cell entry in column 4 Sample size (B/R), which previously read 303/215 should read 49/49. Page 380, Table 1, G-CSF vs. G-CSF section, patients of cohort studies row: the cell entry in column 4 Sample size (B/R), which previously read 2677/17,739 should read 2374/17,524. Page 381, section 3.2.2, paragraph 1, line 1: The sentence, which previously read: Ten cohort studies (2677 patients vs 17,739 patients) should read Nine cohort studies (2374 patients vs 17,524 patients). Fig. 1 PRISMA flowchart of included studies. G-CSF granulocyte colony-stimulating facrs, randomized controlled trial

3 Efficacy and Safety of Supportive Care Biosimilars Among Patients Page 381, section 3.2.2, paragraph 3, line 10: The sentence, which previously read In addition, five cohort studies [40, 41, 45, 48, 49] compared the incidence of FN in cycle 1 in patients treated with filgrastim (860 patients) and filgrastim (6970 patients). should read In addition, four cohort studies [40, 41, 48, 49] compared the incidence of FN in cycle 1 in patients 591 treated with filgrastim (557 patients) and filgrastim (6755 patients). Page 382, Table 3, FN incidence in cycle 1 (3 wk) section, : the s in the / row and the row have been corrected. A corrected version of the table is shown below with the corrected text shown in bold. Table 3 Results for G-CSF Outcomes (follow-up time) Study Group facrs Subgroup No. Sample size (B/R) Heterogeneity test I 2 p Results of meta-analysis Summary effects 95% CI p p-value between subgroups GRADE evidence FN incidence in cycle 1 (3 wk) Drug 4 [53, 56 58] 470/ % RR = Low 4 [28, 50, 51, 59] 582/ % 0.81 RR = [28, 50, 56, 57, 59] 738/ % 0.90 RR = NSCLC 2 [51, 53] 251/ % 0.64 RR = NHL 1 [58] 63/29 RR = G-CSF 8 [28, 50, 51, 53, 55 59] 1052/ % 0.74 RR = [40, 48] 196/ % 0.28 RR = Moderate NHL 1 [41] 12/26 RR = Nonmyeloid 1 [49] 349/6546 RR = [40, 41, 48, 49] 557/ % 0.35 RR =

4 592 J. Yang et al. Outcomes (follow-up time) Study Group facrs Subgroup No. Sample size (B/R) Heterogeneity test I 2 p Results of meta-analysis Summary effects 95% CI p p-value between subgroups GRADE evidence DSN in cycle 1 (3 wk) 7 [28, 50, 52, 54, 57, 1092/ % 0.70 WMD = Moderate NHL 1 [58] 63/29 WMD = Drug 3 [54, 57, 58] 386/ % 0.37 WMD = Moderate 5 [28, 50, 52, 769/ % 0.58 WMD = G-CSF 8 [28, 50, 52, 54, 57 60] 1155/ % 0.66 WMD = Time ANC recovery in cycle 1 (3 wk) 4 [50, 52, 59, 60] 587/ % 0.24 WMD = NSCLC 1 [51] 93/46 WMD = Moderate [49 52, 680/ % 0.37 WMD = NHL 1 [41] 12/26 WMD = Low Bone pain rate (3 30 wk) 2 [54, 59] 512/ % 0.02 RR = NSCLC 1 [53] 158/79 RR = Moderate 0.72 Various tumors 1 [55] 54/54 RR = [53 55, 59] 724/ % 0.10 RR = Various tumors 4 [42 44, 46] 123/ % 0.61 RR = Moderate

5 Efficacy and Safety of Supportive Care Biosimilars Among Patients 593 Outcomes (follow-up time) Study Group facrs Subgroup No. Sample size (B/R) Heterogeneity test I 2 p Results of meta-analysis Summary effects 95% CI p p-value between subgroups GRADE evidence ADE rate (3 30 wk) Drug 4 [29, 54, 56, 60] 674/ % 0.36 RR = Moderate 3 [29, 51, 59] 579/ % 0.07 RR = [28, 29, 54, 56, 59, 60] 1158/ % 0.19 RR = NSCLC 1 [51] 95/50 RR = G-CSF 7 [28, 29, 51, 54, 56, 1253/ % 0.10 RR = Various tumors 1 [47] 1694/10,460 RR = Moderate ADE adverse drug event, ANC absolute neutrophil count, B/R /reference biologics, CI confidence interval, DSN duration of severe (grade 4) neutropenia, FN febrile neutropenia, G-CSF granulocyte colony-stimulating facrs, GRADE Grading of Recommendations Assessment, Development and Evaluation, NHL non-hodgkin s lymphoma, No. number of included studies, NSCLC nonsquamous non smallcell lung, randomized controlled trial, RR risk ratio, WMD weighted mean difference Page 384, Fig. 3, FN incidence in cycle1.cohort section, subgroup: the text in the Study number column that previously read 3 should read 2 ; the text in the Biosimilar sample size column that previously read 499 should read 196 ; the text in Reference sample size column that previously read 398 should read 183 ; the text in the P of meta-analysis column that previously read 0.22 should read 0.15 ; the text in the P between sub-groups column that previously read 0.68 should read 0.43 ; the text in the ES (95% CI) column that previously read 1.36 (0.84, 2.23) should read 1.60 (0.85, 30.1). Page 384, Fig. 3, FN incidence in cycle1.cohort section, F row: the text in the Study number column that previously read 5 should read 4 ; the text in the Biosimilar sample size column that previously read 860 should read 557 ; the text in Reference sample size column that previously read 6970 should read 6755 ; the text in the P of meta-analysis column that previously read 0.36 should read 0.35 ; the text in the ES (95% CI) column that previously read 1.20 (0.81, 1.78) should read 1.25 (0.79, 1.98). A corrected version of Fig. 3 is shown below.

6 594 J. Yang et al. Fig. 3 Meta-analysis of G-CSF biosimilar drugs vs G-CSF drugs. ADE at least one adverse drug event, ANC absolute neutrophil count, CI confidence interval, DSN duration of severe (grade 4) neutropenia, ES effect size, F filgrastim, FN febrile neutropenia, G-CSF granulocyte colony-stimulating facrs, NHL non-hodgkin s lymphoma, NSCLC nonsquamous non small-cell lung, P pegfilgrastim, randomized controlled trial, RR risk ratio, WMD weighted mean differences Page 388, Reference # 45: This reference should be deleted. the text in column patient that previously read 7830 should read 7312 Electronic Supplementary Material, Supplementary Table 3, Puerlas et al [25] row: this row should be deleted. Electronic Supplementary Material, Supplementary Table 5, FN incidence in cycle1 row: the text in column that previously read 5 [20, 21, 25, 27, 28] should read 4 [20, 21, 27, 28] Electronic Supplementary Material, page 9, reference #25: this reference should be deleted

< F63756D656E D2D796E2D31C6DABFAF2D31D6D0D2BDD2A9CFD6B4FABBAF2D C4EA2DB5DA38C6DA2D30362DC3F1D7E5D2BDD2A92E6D6469>

< F63756D656E D2D796E2D31C6DABFAF2D31D6D0D2BDD2A9CFD6B4FABBAF2D C4EA2DB5DA38C6DA2D30362DC3F1D7E5D2BDD2A92E6D6469> 绎 1 2 1. 8300112 援 830000 CNKI 1979-20121989-2013 PubMed/MEDLINE Jadad Cochrane RevMan 5.2.0 Meta 4 360 Meta OS WMD 95%-0.48-0.81-0.160.04-0.150.22 RR 95% 1.671.292.151.220.354.20 doi: 10.11842/wst.2014.08.030